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histologic appearance while they were receiving long-term 
corticosteroId therapy. Untortunately. no data were pre-
sented on the etlcct of corticosteroids on the bone disease 
that is seen with Increasing frequency in patients with PSc. 
Although the characteristics of these bone abnormalities 
have Ilot been thoroughly delineated. the cholestatic na-
ture of PSC and previous data on the metabolic bone dis-
ease ill primar\' hiliary cirrhosis would suggest that the 
hOlle <lbnormalilles In PSC are most likely due to 
llstenporosis. 
. \zathioprine has been used in at least two patients 
wllh PSC without apparent benetlt. Use of low-dose 
methotrexate has recently been reported to cause improve-
ment in results of biochemical studies. in stabilization of 
hile duct scarring. and in liver histologic appearance in 
two patients with PSc. The potential hepatotoxicity of this 
agent and the small number of patients in this report man-
date that this drug not be used until results from controlled 
trials are available. Cyclosporine. a new immunosuppres-
m'e drug that inhibits the production of interleukin-2 by 
T lymphocytes. resulting in decreased T-lymphocyte ac-
ti\'ation and proliteration. is currently under investigatIOn 
at our institution in a double-blind controlled trial. Prelimi-
narv results are not yet available. 
Antifibrogenic Agents 
Recently. considerable enthusiasm for the use of col-
chicine. a drug with putative antifibrogenic effects. has 
emerged because of several controlled trials suggesting ef-
ficacy 111 several types of chronic liver disease. including 
prImary bil iary cirrhosis. To date. there have been no con-
trolled trials of this agent in primary sclerosing cholangitis. 
Combination Drug Therapy 
We recently reported our preliminary experience in 
12 patients with PSC treated with combined prednisone 
and coichicine therapy compared with 12 untreated patients 
SCLEROSING CHOLANGITIS: 
LIVER TRANSPLANTATION 
J. WALLIS MARSH Jr., M.D. 
THO,vlAS E. STARZL, M.D., Ph.D. 
Primary sclerosing cholangitis is a discase of unknown 
etiology but most likely represents an autoimmune dis-
Mdcr. It has a striking prevalence in young men. ages 30 
tn 50. and is. more often than not. associated with intlam-
malmy howel disease. most commonly ulcerative colitis. 
It has. however. also been seen in association with Crohn"s 
matched tor age. sex. initial biochemical test abnormali_ 
ties. and liver histology. We observed impreSSIve improve-
ment in bilirubin. alkaline phosphatase. and aspartate 
aminotransterase leve!s in treated patients when they were 
re-evaluated at 6 and 12 months after entry. The long-term 
cttect of this combination in this open trial is currentlv 
being evaluated. as is the potential toxicitv of both agents 
when used in this syndrome. A prospective controlled ran-
domized trial employing this combination wIll begin short-
ly at the Mayo Clinic . 
Anticholestatic Agents 
Considerable enthusiasm has recently emerged for the 
use of ursodeoxycholic acid in the treatment of cholestat-
ic liver diseases. primarily because of uncontrolled but 
impressive results in a small number of patients with 
primary biliary cirrhosis. The rationale tor the use of ur-
sodeoxycholic acid is to replace bile acids with greater 
toxic potential (e.g .. chenodeoxycholic acid). Although this 
rationale is theoretically attractive in the treatment of a 
cholestatic syndrome like PSc. no data are currently avail-
able regarding its possible benetit. 
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disease. Primary sclerosing cholangitis sometimes pre-
cedes but usually follows by several years the onset of the 
intlammatory bowel disease. 
Primary sclerosing cholangitis is most often classi-
tied as an autoimmune disorder: it is frequently seen in 
patients with the HLA-B8 antigen. Contrary to the auto-
immune etiology is the tact that attempts at immune modu-
lation have been ineffective in signiticantly altering the dis-
ease process. The incidence of primary sclerosing 
cholangitis has been increasing either because of an actual 
increase in the disease or as a result of better diagnostic 
techniques. 
The treatment of sclerosing cholangitis has been 
slowly evolving as the results of liver transplantation have 
improved. Current treatment methods tall into noninter-
ventional and interventional modalities. 
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NONINTERVENTIONAL THERAPY 
~oninteryDentillDK 'reatment has included the use of 
steroids. Jzathiopnr )-penIctllamine. and cholcstyra-
mine. Treatment with steroids or azathioprine attempted 
to alter the course llf the disease through immune suppres-
sion. but long-tCfm results showed little benefit. D-
penicillamine rro\Ilkd ,nme hope. as ~atients with 
primary ,c icmsmg choiangl!ls have been tound to ha\·e 
elevated copper content in the liver. However. long-term 
follow-UP has not shown signiticant beneticial enects. 
Cholestyramine was used in the belief that the disease was 
a result of an abnormal bile acid pool: this. too. has proved 
futile .. \nother chapter on Sclerosing Cholangitis provides 
detail- of medical therapeutic maneuvers. 
INTERVENTIONAL THERAPY 
Radiologic therapy includes percutaneous transhepatic 
cholangiogmphy I PTe) and endoscopic retrograde cholangio-
pancreatography (ERCP) with dilation. with or without 
stenting. We prefer PTC and ERCP because of long-term 
access to the biliary tree if needed. and the comfort of 
the percutaneous long-term stents. Patients with primary 
sclerosing cholangitis should all have an evaluation of the 
biliary tree to contirm the diagnosis and to allow the 
exclusion of cholangiocarcinoma. Any suspicious area of 
the biliary tree should be biopsied and brushings sent tor 
cytologiC examination. 
If the primary sclerosing cholangitis is limited to a 
short segment of the biliary tree (rare). percutaneous 
dilation and stenting can be attempted. This is preferable 
to intraoperative stenting as it is just as effective and does 
not violate the operative tield if transplantation becomes 
necessary. 
Operative Intervention 
Operative intervention (excluding transplantation) 
should become more obsolete in the era of better nonoper-
ative diagnostic techniques. Historically cholecystectomy. 
common duct exploration with biopsies. and the place-
ment l)f a 10mHerm indwelling T-tube were done in the 
hopes that th~ T -tube would ~erve as a stent until the 
primarY sclerosing cholangitis had run its course. 
This. however~ has not -been the usual course. and the 
~lacement of the T -tube only served to violate the opera-
tive tield and provide a nidus for intection. In addition 
to this. l)perative intervention of any type on the biliary 
tree has been suggested to be the most common cause of 
cholangitis in th~;e patients. often hastening their demise 
or need t{)r liver transplantation. 
. \tore recent than the simple placement of aT-tube 
In the gamut of operative interventions has been the use 
~f Silastic stents brought out percutaneously through the 
liver and into the bowel (choledochojejunostomy or 
choledochoduodenosromy). This. too. has not proved to 
be of long-term benetit in most patients and has only served 
to Increase the difficultv of the surgerv in the event that 
transplantation hecome~ necessary.- It 'offers no real ad-
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\anlage over percutaneous stenting. The chapter Scleros-
ing Ch{Flan~i[is: Surgen .tin' Ohstructi\'e Jaundice is 
devoted to transhepatic stentmg tor bifurcation lesions. 
External ostomies that proVide easy access to the 
biliary tree. such as Hudson's loops. should not be per-
t()rmed. since access to the biliary tree can now be gained 
percutaneously. External ostomies cause heavv bacterial 
(olonization of the skin and greatly increase the chance 
for postoperative intection should any intra-abdominal 
procedure become necessary. 
As primary sclerosing cholangitis usually spares syn-
thetic function of the liver until late in the course of the 
disease. patients often present with severe portal hyper-
tension but reasonable liver function. Some of these 
patients have been subjected to elective portal decompres-
sive shunts. This should not be done as an elective proce-
dure because it has no intluence on the disease process 
and only increases the risk of portal vein thrombosis. 
thereby unnecessarily complicating or preventing liver 
transplantation If this is required. 
:-.lone of the above-mentioned surgical procedures 
does anything to modify the course of this unrelenting. 
deadly disease. in tact many of these procedures only serve 
to hasten the terminal stages of the disease and have now 
become antiquated with the advent of better interventional 
radiologic techniques and the option of liver transplanta-
tion. The most frightening aspect of these pacifying tech-
niques is that what was thought to be "'time buving" was. 
in reality. only serving to promote the deveiop~ent of 
cholangiocarcinoma. thus sentencing the patient to death. 
COLECTOMY 
Pretransplant colectomy should not be pertormed 
simply tor the sake of removing the colon prior to liver 
transplantation. If the patient develops carcinoma or 
precarcinomatous changes. then obviously a colectomy 
must be done. Most patients who come to transplantation 
with active colitis can usually be tairly well controlled 
medically. After transplantation most patients enjoy im-
provement in their colitis symptoms. but they should be 
closely tollowed every 6 to 12 months by colonoscopy. 
There are some patients whose colitis seemingly worsened 
several months after transplantation. Colectomy post-
transplantation can be done in the absence of portal hyper-
tension with much less requirement tor blood products. 
In patients who require a colectomy prior to liver 
transplantation. an ileoanal anastomosis should be done 
when possible. This not only eliminates problems with 
peristomal varices but also the constant threat of contami-
nation from an ileostomy 
PATIENT MANAGEMENT 
When a patient with primary sclerosing cholangitis 
is evaluated he or she must have an assessment of liver 
volume. patency of portal vessels. and determination of 
blood type. The computed tomographic scan tor liver 
volume is also used to rule out intra-abdominal pathology. 
particularly cholangiocarcinoma. An assessment of the 
i 
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biliary tree should be made and any suspicIOus lesions 
biopsied and brushed for cytologic examin ... lon. If the 
patient has had a portal decompressive shunt. ~ .. rency must 
be determined. 
Esophagogastroduodenoscopy and colonoscopy 
shoc:,J be done. particularly if the patient has ulcerative 
colitis. Dysplasia and/or carcinoma may be present in 
~ome of these patients with long-standing. often qUiescent 
colitis. In addition to the usual blood chemistries. an as-
.,essment should be made ofliver reserve. As stated earli-
er. however. liver synthetic function is often preserved until 
late in the course of this disease and may give a raise sense 
of security. leaving the patient open to repeated bouts of 
bacterIal perItonitis. bleeding varices from portal hyper-
tensIOn. or cholangiocarcinoma. 
Recommendations for Transplantation 
The timIng of transplantation in patients wah prImary 
sclerosing cholangitis is difficult at best. Transplantation 
is recommended for patients with 
1. 4+ Varices with hypersplenism. 
., Bilirubin higher than 10 mg per deciliter. 
3. History of major variceal bleeding. even with normal 
liver synthetic function. 
4. History of spontaneous bacterial peritonitis. 
5. History of repeated bouts of cholangitis. and 
6. Loss of synthetic liver function. 
These criteria are. however. guesstimates tor patients 
with primary sclerosing cholangitis because of the inci-
dence of undiagnosed cholangiocarcinoma. Unsuspected 
cholangiocarcinoma was found in 10.6 percent (8 of 75) 
of the hepatectomy specimens in our series. and one of 
these patients had only known of his liver disease for I 
year. 
Relative Contraindications 
A thrombosed portal vein on angiogram that is patent 
l)nly in the superior mesenteric branches is a relative con-
traindication to transplantation. Thrombosed portal veins 
open at the cont1uence of the splenic and superiormesen-
teric veins are easily reconstructed. 
Contraindications 
Contraindications to transplantation are (j) patients 
with known cholangiocarcinoma, (2) patients with de-
bilitating systemic disease that would preclude such an 
extensive operation. and (3) nonretormed alcoholics or 
Jrug abusers. 
RESULTS 
Between January 1. 1980, and August l. 1987. 1.018 
primary orthotopic liver transplants were pertormed at the 
Cniversity of Colorado Health Science Center (through 
1980). the University Health Center of Pittsburgh (since 
1981), and the Pittsburgh-affiliated Baylor University 
\Iedical Center at Dallas (since 1985). 
Seventy-five patients received orthotopic liver trans-
plantation tor end-stage primary sclerosing cholangitis. 
Fifty were male (66.6 percent) and 25 were female (33.4 
percent). Their ages ranged from 15 to 63 years. with a 
median age of TI.5 years. Only six patients were older than 
50 years. 
The indications for transplantation were persistent or 
recurrent variceal bleeding in D.2 percent. ascending 
cholangitis in D.2 percent. or the symptoms of end-stage 
liver disease. including encephalopathy, coagulopathy. 
anorexia. ascites. pruritus. and/or 3 to 4+ varices. in 45.5 
percent. 
Bowel Disease 
Fiftv (66.6 percent) of the 75 patients had a history 
of inflammatory bowel disease. Forty-tour had ulcerative 
colitis. and six had Crohn's disease. Eleven patients 
(14.6 percent) had undergone prior bowel surgery either 
tor their inflammatory bowel disease or for complicating 
carcinoma. Ten had undergone partial or total abdominal 
colectomy; one had had a small bowel resection for 
Crohn's disease. 
Four of the 75 patients (50 of whom had inflammatorv 
bowel disease) had had a carcinoma of the colon removed 
11. 11. 4. and 4 years. respectively, prior to liver trans-
plantation without evidence of recurrence. One patient (not 
included in the above group) had a total colectomy 1 year 
after transplant for unmanageable ulcerative colitis and was 
found to have a Duke's B carcinoma. Two of the patients 
who had pretransplant colectomies died within 3 months 
after transplantation from sepsis and liver failure. and 
two are living 20 and 8 months later. Longer follow-up is 
needed to determine cancer recurrence rate under immuno-
suppression. but recurrence this long after colectomy 
would be very surprising. 
Management of the Biliary Tract 
Pretransplantation 
Thirty-eight (50.6 percent) of the 75 patients had 
undergone prior violation of the biliary tract tor diagno-
sis or treatment of the sclerosing cholangitis. Sixteen 
patients had undergone hepaticojejunostomy, ten cholecys-
tectomy alone, six T-tube drainage of the choledochus. 
three cholecystectomy and percutaneous choledochal 
drainage. one choledochoduodenostomy. one choledocho-
jejunostomy, and one cholecystojejunostomy. 
liver Disease Prior to Transplantat: n 
The liver disease was diagnosed I to 16 years (mean 
5.8 years) prior to transplantation, and the bowel disease. 
when present. had existed from 2 to 30 years (mean 14.8 
years), In all but five of the 50 cases with coexistent 
inflammatory bowel disease. the bowel disease preceded 
the sclerosing cholangitis. 
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SURVIVAL 
As of October l. 1987. there were 52 patients living 
(69.3 percent) and :l dead (30.6 perce''''I. with a mean 
follow-up of 19 mon;:, (range 1 to 61' ·[hs). The actu-
arial survival rates were l. . .:ulated cUli1paring the group 
including those with cholangiocarcinoma to the same 
group not including those with cholangiocarcinoma. 
Actuarial survival rates "'ere calculated using the survival 
analysis modules in BMDP/PC (BMDP Statistical Soft-
ware. Los Angeles. CAl on an IBM/PC-AT microcom-
puter. The data are presented in Table I. 
CAUSE OF DEATH 
Thirteen patients died within 3 months of transplan-
tation. all from direct complications of transplantation or 
the associated immunosuppression. Technical failures. 
primary non function of the graft. intectious complications. 
and irreversible acute rejection were the leading causes 
of death. Three patients died between 3 and 6 months. 
two from graft failure and sepsis and another from biliary 
sepsis due to recurrence of cholangiocarcinoma. Between 
6 and 12 months. one patient died from an unrecognized 
lymphoproliferative disorder. Five patients died between 
1 and 2 years. three from recurrent cholangiocarcinoma. 
one from systemic fungal infection. and the other from 
gastrointestinal bleeding and liver failure due to rethrom-
basis of the portal and superior mesenteric veins that had 
been opened with thrombophlebectomy at the time of 
transplantation. No patients died between 2 and 3 years 
after transplant. One patient died from liver failure due 
to chronic rejection more than 3 years after transplantation. 
Unrecognized Cholangiocarcinoma 
Previously unrecognized cholangiocarcinoma was 
found in the surgical specimens of eight of the 75 patients 
(10.6 percent). There were five males and three females 
with an average age of 44.6 years (range 24 to 61). Three 
had no history of inflammatory bowel disease: five had 
a historv of ulcerative colitis. The clinicallv evident liver 
disease had been present for 1 to 14 years (m"ean 6.5 years), 
clearly demonstrating that long-standing liver disease 
is not a prerequisite for the development of cholangio-
carcinoma. Five of these eight patients died as a result of 
recurrent cholangiocarcinoma 4. 12, 12. 14 and 15 months 
after transplant;tion. One patient died of accelerated 
TABLE 1 Post-Transplantation Survival 
(Percent Survival by Months) 
Including Excluding 
OlOiangioc(lTCinoma Cho/(lnglO('arcinoma 
J months 94% 95% 
6 months 85% 85% 
12 months 8\ o/c 82% 
O~ months 78% 80% 
36 months 67% 73% 
~U months 67% 73% 
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rejection less than 2 weeks after transplantation. Two 
patients are alive and well without evidence of recurrence 
at 21 and 21 months after transplantation. All of the 
hepatectomy specimens from the patients with cholan-
giocarcinoma showed separate areas of sclerosing cholan-
gitis. thereby excluding the possibility that any of these 
patients was wrongly classified as having sclerosing 
cholangitis instead of only cholangiocarcinoma. 
Recurrence of Sclerosing Cholangitis 
As primary sclerosing cholangitis is believed to be 
an autoimmune disorder. the disease process should recur. 
Only one patient who received a transplant for primary 
sclerosing cholangitis developed chemical and radiologic 
abnormalities in the graft compatible with sclerosing 
cholangitis 1 year after transplantation. but the abnormal-
ities have remained stable for the ensuing 2 years. Four 
other patients whose original liver disease was not scleros-
ing cholangitis have also developed similar abnormalities 
after histologically proven graft rejection. 
DISCUSSION 
Sclerosing cholangitis is an enigmatic disease. the 
incidence of which is increasing. It is a cholestatic dis-
ease, probably autoimmune in nature. With an expansion 
of the diagnostic armamentarium. there may be found a 
particular subset of patients who have only laboratory 
abnormalities and minor bile duct changes and whose con-
ditions never progress to end-stage liver disease. However. 
at this time. primary sclerosing cholangitis must be con-
sidered a pernicious disease that is precancerous. It is 
difficult to determine the number of patients who will 
actually develop cholangiocarcinoma. but as reported 
above. 10.6 percent of our transplant population had 
unsuspected lesions. For every patient receiving a trans-
plant who was found to have cholangiocarcinoma in the 
hepatectomy specimen. at least one was refused transplan-
tation because of known cholangiocarcinoma. It has been 
suggested that these patients be followed by serial biopsies 
until atypical changes suggestive of precholangiocarcinoma 
are found and then they may receive transplants. However. 
this should not be done. as many of our patients showed 
only atypical changes on biopsy before transplantation but 
had terminally advanced cholangiocarcinoma in their 
hepatectomy specimens. 
Timing of Transplantation 
The fact that synthetic liver function is preserved in 
spite of often severe portal hypertension plus the danger 
of choiangiocarcinoma make the timing of transplantation 
difficult at best. Many of these patients come to transplan-
tation because of complications from prior surgeries. Even 
though it is impossible to exactly determine, the ideal time 
for transplantation is the day before the patient develops 
cholangiocarcinoma. Until such time that atypical changes 
on biopsy truly represent preinvasive carcinoma and not 
& 
168/ Current Management of Intlammatory Bowel Disease 
underlying invasive carcinoma. only guidelines such as 
those presented above can be followed. 
In the absence of cholangiocarcinoma. the survival 
rate for I iver transplantation is excellent (73 percent at 4 
years). and the patients are able to resume normal lives. 
Perhaps with the wider application of monoclonal anti-
bodies. a method will be tound to identify the earliest 
changes of eholangiocarcinoma. thus maximizing as much 
as possible both the timing of transplantation and patient 
survival. 
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Sclerosing cholangitis is a rare disease characterized 
bv fibrous thickening of the walls of the bile ducts that 
cannot be attributed to other diseases. The cause or causes 
of sclerosing cholangitis remain unknown, but several etio-
logic theories such as autoimmune. bacterial. congenital. 
and viral have been proposed. The disease most closely 
associated with sclerosing cholangitis is inflammatory 
bowel disease. Although sclerosing cholangitis has been 
associated with Crohn's disease. the vast majority of pa-
tients with sclerosing cholangitis and inflammatory bowel 
disease have ulcerative colitis. The incidence of ulcera-
tive colitis in recent series of patients with sclerosing 
cholangitis ranges from 29 percent to 72 percent and aver-
ages about 50 percent. At the time of presentation with 
sclerosing cholangitis. the colitis is usually mild or the 
patient has had a prior colectomy. 
The clinical course of patients with sclerosing cholan-
gitis may be quite variable. Some patients may be diag-
nosed because of mild liver function abnormalities and 
may remain asymptomatic for years. However. other pa-
t lents have a rapidly progressive course and may die soon 
after diagnosis from liver failure. Moreover. many patients 
have exacerbations and remissions. and in some patients 
the bile ducts have been documented radiologically to 
revert back to near normal. Because of the variable clini-
cal course and the rarity of the disease. response to treat-
ment has been difficult to evaluate. Nevertheless. a 
multitude of medical and surgical options has been tried. 
suggesting that the ideal torm of treatment has not yet been 
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found. However. based on our recent experience, we be 
lieve that a direct surgical approach to the biliary tree wit 
prolonged transhepatic stenting is the optimal treatmer 
for those patients with severe hilar or extrahepatic stric 
turing. persistent jaundice and/or recurrent cholangitis. an 
no biopsy evidence of cirrhosis. 
TREATMENT ALTERNATIVES 
A summary of treatment options and outcomes I 
presented in Table I. Alternatives include drug therap~ 
nasobiliary lavage. balloon dilation. hepaticojejunostom 
in conjunction with postoperative balloon dilation or tran~ 
hepatic stenting, and hepatic transplantation. 
Drug Therapy 
No known specific effective medical therapy is avail 
able for sclerosing cholangitis. even though numerou 
approaches with various drug therapies alone or in com 
bination have been trie(: Specifically. corticosteroid~ 
azathioprine. and D-peml ... Jmine have been tried in larg 
numbers of patients. but none of these drugs has prove. 
helpful. Colchicine has recently been reported to produc 
improvement in a few patients. but much more experienc 
is required for efficacy to be proved. Symptomatic relit 
of pruritus can often be obtained with cholestyramine 
however. this bile salt binding agent has not been demon 
strated to alter the course of sclerosing cholangitis. Anti 
biotics may also be beneficial when patients have feVel 
In general. however. antibiotics effective against biliar 
flora should be reserved tor episodes of cholangitis an, 
not for long-term administration. 
Nasobiliary lavage 
Recently. nasobiliary lavage with steroids has bee: 
attempted in patients with sclerosing cholangiti, 
Nasobiliary tubes were placed endoscopically, and patient 
were randomized to receive continuous biliary lavage WII' 
